Compare Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Innov-100 0DTE Covered Call Strat ETF vs Smith & Nephew plc — how do they compare? Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.5 (market cap $962.24M), while Smith & Nephew plc trades at $27.23 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 11.5× Roundhill Innov-100 0DTE Covered Call Strat ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Innov-100 0DTE Covered Call Strat ETF for 56 Days and Smith & Nephew plc for 120 Days on average.
| QDTE | SNN | |
|---|---|---|
Market Cap | $962.24M | $11.10B |
Volume | 882,859 | 1,051,703 |
Sector | Income / Options Overlay | Health |
52-Week High | $36.60 | $37.17 |
52-Week Low | $26.85 | $26.42 |
Typical Hold Time | 56 Days | 120 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QDTE trades at $29.89, down 0.3% with a bullish technical signal despite overbought RSI readings. The ETF generates weekly income through covered call strategies but faces concerns about NAV erosion and return of capital. Recent distributions have declined from $0.28 to $0.11, reflecting shrinking yields as volatility decreases. The fund's 0.97% expense ratio consumes significant portions of payouts, creating structural challenges for long-term value preservation.
The outlook remains cautious as high distribution yields mask underlying NAV deterioration. While weekly income appeals to retail investors, the strategy underperforms in bull markets and faces sustainability questions. Key risks include volatility dependency, return of capital concerns, and competitive pressure from alternative income ETFs. Analyst sentiment is mixed with recent downgrades highlighting structural weaknesses.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
